At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
GIPR Generation Income Properties Inc.
Market Closed 12-12 16:00:00 EST
0.9597
-0.1903
-16.55%
盘后0.9613
+0.0016+0.17%
19:59 EST
High1.08Low0.9012Vol534.70K
Open1.05D1 Closing1.15Amplitude15.54%
Mkt Cap5.23MTradable Cap4.30MTotal Shares5.45M
T/O520.95KT/O Rate11.93%Tradable Shares4.48M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development
Stock News  ·  11-30
ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
prnewswire  ·  11-30
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
Generation Income Q3 FFO $0.03 Beats $(0.08) Estimate, Sales $2.470M Beat $2.432M Estimate
Benzinga  ·  11-18
Generation Income Q3 FFO $0.03 Beats $(0.08) Estimate, Sales $2.470M Beat $2.432M Estimate
Generation Income Properties Reports Q3 2025 Financial and Operating Results
Reuters  ·  11-18
Generation Income Properties Reports Q3 2025 Financial and Operating Results
ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development
Stock News  ·  11-13
ASCLETIS-B (01672): Monthly-Dose Next-Gen Amylin Receptor Agonist ASC36 and GLP-1R/GIPR Dual-Target Agonist ASC35 Combo Advances to Clinical Development
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
prnewswire  ·  11-13
Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
Press Release: Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Dow Jones  ·  11-11
Press Release: Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Generation Income Properties Inc Announces Date for Upcoming Stockholder Meeting
Reuters  ·  11-08
Generation Income Properties Inc Announces Date for Upcoming Stockholder Meeting
Generation Income Properties Sells Vacant Florida Industrial Property for $1.95 Million
Reuters  ·  11-06
Generation Income Properties Sells Vacant Florida Industrial Property for $1.95 Million
Generation Income Properties Extends Promissory Note Maturity to December 2025
Reuters  ·  11-01
Generation Income Properties Extends Promissory Note Maturity to December 2025
Hengrui's Class 1 Innovative Drug HRS-4729, a GLP-1R/GIPR/GCGR Triple Receptor Agonist, Receives Clinical Trial Approval for Metabolic Associated Fatty Liver Disease/Metabolic Associated Steatohepatitis
Deep News  ·  09-12
Hengrui's Class 1 Innovative Drug HRS-4729, a GLP-1R/GIPR/GCGR Triple Receptor Agonist, Receives Clinical Trial Approval for Metabolic Associated Fatty Liver Disease/Metabolic Associated Steatohepatitis
Generation Income Properties Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Equity Requirements
Reuters  ·  08-23
Generation Income Properties Inc. Faces Potential Delisting from Nasdaq Due to Non-Compliance with Equity Requirements
David Sobelman, Chairman, President, and CEO, Reports Acquisition of Common Shares in Generation Income Properties Inc
Reuters  ·  08-22
David Sobelman, Chairman, President, and CEO, Reports Acquisition of Common Shares in Generation Income Properties Inc
Generation Income Properties Secures Early Lease Extension with Best Buy, Increasing Rent and Reinforcing Commitment
Reuters  ·  08-21
Generation Income Properties Secures Early Lease Extension with Best Buy, Increasing Rent and Reinforcing Commitment
ASCLETIS-B (01672): ASC47 Combined with GLP-1R/GIPR Dual Receptor Agonist Peptide ASC31 Demonstrates Superior Weight Loss Effects Compared to ASC47 Plus Tirzepatide Combination in Obese Animal Models
Stock News  ·  08-18
ASCLETIS-B (01672): ASC47 Combined with GLP-1R/GIPR Dual Receptor Agonist Peptide ASC31 Demonstrates Superior Weight Loss Effects Compared to ASC47 Plus Tirzepatide Combination in Obese Animal Models
Generation Income Properties Inc. Delays Filing of Q2 2025 Financial Report Due to Debt Analysis
Reuters  ·  08-15
Generation Income Properties Inc. Delays Filing of Q2 2025 Financial Report Due to Debt Analysis
Generation Income Properties' Subsidiary Secures Year-Long Extension of Preferred Equity Maturity
Reuters  ·  08-14
Generation Income Properties' Subsidiary Secures Year-Long Extension of Preferred Equity Maturity
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire  ·  08-06
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Generation Income Properties Inc. Announces Strategic Alternatives and Recapitalization Efforts Amid Market Challenges
Reuters  ·  07-01
Generation Income Properties Inc. Announces Strategic Alternatives and Recapitalization Efforts Amid Market Challenges
BRIEF-Shareholder Resurgent Realty Trust Says Generation Income Properties Board Should Be Reconstituted
Reuters  ·  06-25
BRIEF-Shareholder Resurgent Realty Trust Says Generation Income Properties Board Should Be Reconstituted

Introduction

Company Name.
Generation Income Properties Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Generation Income Properties, Inc., located in Tampa, Florida, is an internally managed real estate investment trust formed to acquire and own, directly and jointly, real estate investments focused on retail, office, and industrial net lease properties in densely populated submarkets.
Issue price:
--